Similar results concerning the potential predictive role of circulated EGFR have been demonstrated in a phase II study with locally advanced esophagogastric cancer [37] as well as in a cohort of 102 NSCLC patients receiving an anti-EGFR therapy [38]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.